Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID‐19
Bharat Damle, Manoli Vourvahis, Erjian Wang, et al.
Clinical Pharmacology & Therapeutics (2020) Vol. 108, Iss. 2, pp. 201-211
Open Access | Times Cited: 172

Showing 1-25 of 172 citing articles:

Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase
Muhammad Usman Mirza, Matheus Froeyen
Journal of Pharmaceutical Analysis (2020) Vol. 10, Iss. 4, pp. 320-328
Open Access | Times Cited: 270
Azithromycin in the treatment of COVID-19: a review
Daniel Echeverría-Esnal, Clara Martín‐Ontiyuelo, María Eugenia Navarrete-Rouco, et al.
Expert Review of Anti-infective Therapy (2020) Vol. 19, Iss. 2, pp. 147-163
Open Access | Times Cited: 233
Self-medication practices during the COVID-19 pandemic among the adult population in Peru: A cross-sectional survey
Jean Franco Quispe-Cañari, Evelyn Fidel-Rosales, Diego Manrique, et al.
Saudi Pharmaceutical Journal (2020) Vol. 29, Iss. 1, pp. 1-11
Open Access | Times Cited: 231
Natural history of COVID-19 and current knowledge on treatment therapeutic options
Wagner Gouvêa dos Santos
Biomedicine & Pharmacotherapy (2020) Vol. 129, pp. 110493-110493
Open Access | Times Cited: 212
Hypoxia, HIF-1α, and COVID-19: from pathogenic factors to potential therapeutic targets
Zoya Serebrovska, Elisa Chong, Tatiana V. Serebrovskaya, et al.
Acta Pharmacologica Sinica (2020) Vol. 41, Iss. 12, pp. 1539-1546
Open Access | Times Cited: 185
COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics
Samy A. Azer
New Microbes and New Infections (2020) Vol. 37, pp. 100738-100738
Open Access | Times Cited: 149
Natural history of COVID-19 and therapeutic options
Philippe Gautret, Matthieu Million, Pierre‐André Jarrot, et al.
Expert Review of Clinical Immunology (2020) Vol. 16, Iss. 12, pp. 1159-1184
Closed Access | Times Cited: 143
Azithromycin in viral infections
Madeleine Oliver, Timothy S.C. Hinks
Reviews in Medical Virology (2020) Vol. 31, Iss. 2
Open Access | Times Cited: 142
Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements
Abhjieet Pandey, Ajinkya Nitin Nikam, Ajjappla Basavaraj Shreya, et al.
Life Sciences (2020) Vol. 256, pp. 117883-117883
Open Access | Times Cited: 131
An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?
Omkar Indari, Shweta Jakhmola, E. Manivannan, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 86
COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs
Alessandra Bartoli, Filippo Gabrielli, Tatiana Alicandro, et al.
Internal and Emergency Medicine (2021) Vol. 16, Iss. 2, pp. 281-308
Open Access | Times Cited: 78
Rationale for azithromycin in COVID-19: an overview of existing evidence
Iwein Gyselinck, Wim Janssens, Peter Verhamme, et al.
BMJ Open Respiratory Research (2021) Vol. 8, Iss. 1, pp. e000806-e000806
Open Access | Times Cited: 72
Widely available lysosome targeting agents should be considered as potential therapy for COVID-19
Jan Homolak, Ivan Kodvanj
International Journal of Antimicrobial Agents (2020) Vol. 56, Iss. 2, pp. 106044-106044
Open Access | Times Cited: 70
Antihistamines and azithromycin as a treatment for COVID-19 on primary health care – A retrospective observational study in elderly patients
Juan Ignacio Morán Blanco, Judith A. Alvarenga Bonilla, Sakae Homma, et al.
Pulmonary Pharmacology & Therapeutics (2021) Vol. 67, pp. 101989-101989
Open Access | Times Cited: 65
Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy
Mona Sadat Mirtaleb, Amir Hossein Mirtaleb, Hassan Nosrati, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 138, pp. 111518-111518
Open Access | Times Cited: 60
The management of surgical patients in the emergency setting during COVID-19 pandemic: the WSES position paper
Belinda De Simone, Élie Chouillard, Massimo Sartelli, et al.
World Journal of Emergency Surgery (2021) Vol. 16, Iss. 1
Open Access | Times Cited: 55
Candidate antiviral drugs for COVID-19 and their environmental implications: a comprehensive analysis
Partha Biswas, Mohammad Mehedi Hasan, Dipta Dey, et al.
Environmental Science and Pollution Research (2021) Vol. 28, Iss. 42, pp. 59570-59593
Open Access | Times Cited: 55
Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period
Danyi Ao, Xuemei He, Jian Liu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 27
Injectable Hydrogel To Deliver Bone Mesenchymal Stem Cells Preloaded with Azithromycin To Promote Spinal Cord Repair
Yujie Wan, Yan Lin, Tan Xie, et al.
ACS Nano (2024) Vol. 18, Iss. 12, pp. 8934-8951
Closed Access | Times Cited: 9
The eye as the discrete but defensible portal of coronavirus infection
Minas T. Coroneo
The Ocular Surface (2020) Vol. 19, pp. 176-182
Open Access | Times Cited: 57
Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19
Chengyin Liu, Ying Wen, Weiguo Wan, et al.
International Immunopharmacology (2020) Vol. 90, pp. 107157-107157
Open Access | Times Cited: 53
Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey
Pedro Mondéjar-López, Esther Quintana Gallego, Rosa Girón, et al.
Respiratory Medicine (2020) Vol. 170, pp. 106062-106062
Open Access | Times Cited: 49
Efficacy and safety of azithromycin in Covid‐19 patients: A systematic review and meta‐analysis of randomized clinical trials
Ahmed Kamel, Mona S. Abdel Monem, Nour A. Sharaf, et al.
Reviews in Medical Virology (2021) Vol. 32, Iss. 1
Open Access | Times Cited: 49
Races of small molecule clinical trials for the treatment of COVID‐19: An up‐to‐date comprehensive review
Suwen Hu, Songwei Jiang, Qi Xiang, et al.
Drug Development Research (2021) Vol. 83, Iss. 1, pp. 16-54
Open Access | Times Cited: 46
Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021
Safaet Alam, Taslima Binte Kamal, Md. Moklesur Rahman Sarker, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 42
Page 1 - Next Page

Scroll to top